Impact of APP-assisted Patient Management on the Quality Control of Blood Purification Therapy

December 5, 2025 updated by: Yunfeng Xia

Many maintenance hemodialysis (MHD) patients develop negative outlooks due to their illnesses and complications, making their quality of life and prognosis a clinical concern. Effective life management and treatment cooperation are crucial to improving dialysis quality and patient outcomes. This trial aims to evaluate whether management through the "Yueya" mini-program and WeChat can provide personalized guidance such as health education, diet, exercise, medication supervision, and condition monitoring to enhance treatment compliance, quality of life, strengthen quality control in the hemodialysis unit, and improve patient prognosis.

Patients will be divided into a group receiving support via the "Yueya" mini-program and WeChat, and a control group receiving routine care. Clinical and laboratory indicators, cardiovascular events, death, hospitalization, quality of life, and compliance will be recorded and compared between groups to assess the impact of APP-assisted patient management on the quality of MHD blood purification therapy and the prognosis of MHD patients.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Affected by their own diseases and various complications, many maintenance hemodialysis (MHD) patients have a negative and pessimistic attitude toward life. Their quality of life and prognosis have always been a concern for clinicians. Therefore, how to adjust and manage the lives of these patients, enable them to actively cooperate with various treatment methods, maximize the quality of blood purification therapy, and improve their quality of life and prognosis has become an extremely important research topic.

Study Type

Interventional

Enrollment (Estimated)

392

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, China, 400016
        • Recruiting
        • The First Affiliated Hospital of Chongqing Medical University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients with stage 5 chronic kidney disease, who have received maintenance hemodialysis for more than 3 months, are aged between 18 and 75 years old, and have regular dialysis three times a week.
  • Patients with relatively stable condition, who are able to take care of themselves and willing to cooperate with the study.
  • Patients who can understand and proficiently use WeChat and the "Yueya" mini - program used in this study.

Exclusion Criteria:

  • Patients with communication barriers or other conditions that prevent them from cooperating with the study.
  • Patients who have a history of acute myocardial infarction, cerebral infarction or intracerebral hemorrhage in the past six months.
  • Patients who are not willing to actively cooperate with the study.
  • Patients with severe liver cirrhosis, active tuberculosis and AIDS.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: APP management group
For the APP management group, according to the specific conditions of patients such as age, gender, primary disease and complications, the "Yueya" mini-program and WeChat will be used to provide individualized and all-weather guidance for dialysis patients in their daily lives, including health knowledge education, diet and exercise guidance, medication supervision, condition monitoring and real-time feedback.
Behavioral: APP-based management
Based on patients' specific conditions such as age, gender, primary disease, and complications, the APP-based management will provide individualized and round-the-clock guidance for dialysis patients in their daily lives through the "Yueya" mini-program and WeChat. This guidance covers various aspects, including health knowledge education, diet and exercise guidance, medication supervision, condition monitoring, and real-time feedback.
No Intervention: Non-APP management group
For the non-APP management group, the APP mini-program will not be used to guide patients' daily lives, and only the previous routine management methods will be adopted.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
mortality rate
Time Frame: About 1 year
In this study, mortality rate was used as a prognostic indicator.
About 1 year
Hospitalization rate
Time Frame: About 1 year
In this study, the hospitalization rate was used as a prognostic indicator.
About 1 year
Kidney Disease Quality of Life
Time Frame: About 1 year
Measuring the quality of life of hemodialysis patients through the Kidney Disease Quality of Life-36（KDQOL-36） scale. If the KDQOL-36 score increases, the quality of life is considered to be improved.
About 1 year
Incidence of cardiovascular events
Time Frame: About 1 year
About 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Yunfeng Xia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 22, 2025

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

September 18, 2025

First Submitted That Met QC Criteria

December 5, 2025

First Posted (Actual)

December 18, 2025

Study Record Updates

Last Update Posted (Actual)

December 18, 2025

Last Update Submitted That Met QC Criteria

December 5, 2025

Last Verified

October 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1st ChongqingMedicalUniversity

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on End Stage Renal Disease (ESRD)

Clinical Trials on APP-based management

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe